Introduction:

Drug discovery faces many challenges, most notably the low rate of progression from drug candidate to market
release and the looming patent expiration of many best-selling drugs. This has increased the pressure on
pharmaceutical companies to identify novel drug targets and lead molecules. VisionSort, a breakthrough platform leveraging Ghost Cytometry technology, provides a transformative solution. Ghost Cytometry leverages high-resolution morphological profiling and AI to provide a unique and holistic measure of cellular phenotype that can be leveraged for drug screening, enabling researchers to screen for new, complex disease-associated phenotypes
that are not possible to find using conventional methods. In addition, the approach can be used to identify new drug targets as well as novel, rare, and disease-associated cell populations. 

Summary:

In this White Paper we discuss:

-The challenges facing drug discovery, particularly the increasing complexity of drug development.
• The current landscape of life science approaches used in drug discovery and their limitations.
• An overview of Ghost Cytometry technology and its key benefits over current approaches.
• Case studies showing real-world applications of VisionSort to advance drug discovery.

Register to find out more.